IN2014MN01465A - - Google Patents
Info
- Publication number
- IN2014MN01465A IN2014MN01465A IN1465MUN2014A IN2014MN01465A IN 2014MN01465 A IN2014MN01465 A IN 2014MN01465A IN 1465MUN2014 A IN1465MUN2014 A IN 1465MUN2014A IN 2014MN01465 A IN2014MN01465 A IN 2014MN01465A
- Authority
- IN
- India
- Prior art keywords
- hcv
- inhibitors
- meaning
- preparing
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11195840 | 2011-12-28 | ||
PCT/EP2012/076934 WO2013098313A1 (en) | 2011-12-28 | 2012-12-27 | Hetero-bicyclic derivatives as hcv inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01465A true IN2014MN01465A (xx) | 2015-04-17 |
Family
ID=47505011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1465MUN2014 IN2014MN01465A (xx) | 2011-12-28 | 2012-12-27 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9126986B2 (xx) |
EP (1) | EP2797911B1 (xx) |
JP (1) | JP6170944B2 (xx) |
CN (1) | CN104203940B (xx) |
AU (1) | AU2012360905B2 (xx) |
BR (1) | BR112014016157A8 (xx) |
CA (1) | CA2858659A1 (xx) |
ES (1) | ES2558608T3 (xx) |
IN (1) | IN2014MN01465A (xx) |
MX (1) | MX340033B (xx) |
RU (1) | RU2621734C1 (xx) |
WO (1) | WO2013098313A1 (xx) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9303061B2 (en) | 2011-07-09 | 2016-04-05 | Sunshine Luke Pharma Co., Ltd. | Spiro compounds as Hepatitis C virus inhibitors |
JP6199891B2 (ja) * | 2011-12-28 | 2017-09-20 | ヤンセン・サイエンシズ・アイルランド・ユーシー | Hcv阻害剤としてのキナゾリノン誘導体 |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
US9775831B2 (en) | 2013-07-17 | 2017-10-03 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of HCV |
CN104860931A (zh) * | 2014-02-21 | 2015-08-26 | 常州寅盛药业有限公司 | 丙肝病毒抑制剂及其制药用途 |
WO2017023631A1 (en) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN108349945B (zh) * | 2015-11-06 | 2021-10-29 | 江苏豪森药业集团有限公司 | Hcv抑制剂、其制备方法与应用 |
CN106946775B (zh) * | 2016-01-07 | 2020-04-10 | 清华大学 | 一种化合物及其在制备抗丙肝病毒药物中的应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
AU723730B2 (en) | 1996-04-23 | 2000-09-07 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of IMPDH enzyme |
JP4327910B2 (ja) | 1997-03-14 | 2009-09-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | Impdh酵素のインヒビター |
CZ301802B6 (cs) | 1999-03-19 | 2010-06-30 | Vertex Pharmaceuticals Incorporated | Deriváty mocoviny jako inhibitory IMPDH a farmaceutické prostredky s jejich obsahem |
WO2000057877A1 (en) | 1999-03-26 | 2000-10-05 | Euro-Celtique S.A. | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US20030005443A1 (en) | 2001-06-27 | 2003-01-02 | Karin Axelsson | EPG having PIP window history and sample view functionality |
CN100484933C (zh) | 2002-06-19 | 2009-05-06 | 比奥维特罗姆股份公开公司 | 新的吡嗪化合物及其在制备用于治疗与5-羟色胺相关的疾病的药物中的用途 |
WO2004005264A2 (en) | 2002-07-05 | 2004-01-15 | Axxima Pharmaceuticals Ag | Imidazole compounds for the treatment of hepatitis c virus infections |
WO2004050035A2 (en) | 2002-12-03 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
WO2007000706A2 (en) | 2005-06-29 | 2007-01-04 | Koninklijke Philips Electronics N.V. | Block signature based data transfer |
PE20070343A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
WO2007039578A1 (en) | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted azabenzophenone compounds |
NO324811B1 (no) | 2005-12-22 | 2007-12-10 | Norsk Hydro Produksjon As | Undervannspumpe |
JP2009520735A (ja) | 2005-12-22 | 2009-05-28 | スミスクライン・ビーチャム・コーポレイション | 抗ウイルス性2−カルボキシ−チオフェン化合物 |
CA2648923A1 (en) | 2006-04-11 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases |
FR2900404B1 (fr) | 2006-04-27 | 2008-07-18 | Sod Conseils Rech Applic | Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7923004B2 (en) | 2006-10-13 | 2011-04-12 | Xtl Biopharmaceuticals Ltd. | 4-ethynyl pyrazole derivative compounds and methods for treatment of HCV |
WO2008070447A2 (en) | 2006-11-21 | 2008-06-12 | Smithkline Beecham Corporation | Anti-viral compounds |
GB0707092D0 (en) | 2007-04-12 | 2007-05-23 | Smithkline Beecham Corp | Compounds |
ES2383388T3 (es) | 2008-02-12 | 2012-06-20 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis C |
US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
NZ587557A (en) | 2008-02-13 | 2012-04-27 | Bristol Myers Squibb Co | Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors |
US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN104163816A (zh) | 2008-12-03 | 2014-11-26 | 普雷西迪奥制药公司 | Hcv ns5a的抑制剂 |
CA2750577A1 (en) * | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
MY160130A (en) | 2009-02-27 | 2017-02-28 | Enanta Pharm Inc | Hepatitis c virus inhibitors |
US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AP3622A (en) | 2009-05-13 | 2016-03-02 | Gilead Sciences Inc | Antiviral compounds |
JP2012533569A (ja) | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
EP2475256A4 (en) * | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
MX2012010918A (es) * | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
TW201141857A (en) * | 2010-03-24 | 2011-12-01 | Vertex Pharma | Analogues for the treatment or prevention of flavivirus infections |
WO2012013643A1 (en) * | 2010-07-26 | 2012-02-02 | Tibotec Pharmaceuticals | Hetero-bicyclic derivatives as hcv inhibitors |
-
2012
- 2012-12-27 WO PCT/EP2012/076934 patent/WO2013098313A1/en active Application Filing
- 2012-12-27 IN IN1465MUN2014 patent/IN2014MN01465A/en unknown
- 2012-12-27 ES ES12810310.8T patent/ES2558608T3/es active Active
- 2012-12-27 JP JP2014549459A patent/JP6170944B2/ja not_active Expired - Fee Related
- 2012-12-27 EP EP12810310.8A patent/EP2797911B1/en not_active Not-in-force
- 2012-12-27 MX MX2014008041A patent/MX340033B/es active IP Right Grant
- 2012-12-27 CA CA2858659A patent/CA2858659A1/en not_active Abandoned
- 2012-12-27 AU AU2012360905A patent/AU2012360905B2/en not_active Ceased
- 2012-12-27 RU RU2014130985A patent/RU2621734C1/ru not_active IP Right Cessation
- 2012-12-27 BR BR112014016157A patent/BR112014016157A8/pt not_active Application Discontinuation
- 2012-12-27 CN CN201280065104.XA patent/CN104203940B/zh not_active Expired - Fee Related
- 2012-12-27 US US14/368,335 patent/US9126986B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
BR112014016157A2 (pt) | 2017-06-13 |
MX340033B (es) | 2016-06-21 |
MX2014008041A (es) | 2014-08-21 |
EP2797911A1 (en) | 2014-11-05 |
AU2012360905A1 (en) | 2014-06-26 |
ES2558608T3 (es) | 2016-02-05 |
CA2858659A1 (en) | 2013-07-04 |
WO2013098313A1 (en) | 2013-07-04 |
CN104203940B (zh) | 2017-01-18 |
EP2797911B1 (en) | 2015-10-28 |
JP2015503536A (ja) | 2015-02-02 |
CN104203940A (zh) | 2014-12-10 |
US9126986B2 (en) | 2015-09-08 |
AU2012360905B2 (en) | 2017-04-27 |
JP6170944B2 (ja) | 2017-07-26 |
RU2621734C1 (ru) | 2017-06-07 |
US20140357626A1 (en) | 2014-12-04 |
BR112014016157A8 (pt) | 2017-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502355A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
PH12018501812A1 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
IN2014MN01465A (xx) | ||
PH12016500723B1 (en) | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
PH12016500027A1 (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
MX2015011229A (es) | Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b. | |
MX2015015771A (es) | Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b. | |
MX353412B (es) | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
PH12015500386A1 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
PH12015500780A1 (en) | Rsv antiviral compounds | |
EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
IN2014MN01486A (xx) |